Pluri (PLUR) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pluri (PLUR) has outperformed Senti Biosciences (SNTI) over the past year, losing 75.5% versus a loss of 81.9%. Over five years, PLUR leads with a -95.2% price change compared with -99.7% for SNTI. Pluri is the larger company by market cap ($12.6 million vs $10.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLUR | SNTI |
|---|---|---|
| Share price | $1.00 | $0.3217 |
| Market cap | $12.61M | $10.02M |
| 1-day change | -3.85% | -2.52% |
| YTD return | -66.56% | -69.07% |
| 1-year return | -75.49% | -81.93% |
| 5-year return | -95.23% | -99.68% |
| EPS (TTM) | $-2.44 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.87 | $2.88 |
| 52-week low | $0.85 | $0.29 |
| Distance from 52-week high | -79.47% | -88.83% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +4096.46% |
| Average volume | 24.97K | 573.78K |
| Shares outstanding | 12.61M | 31.15M |
| Employees | 92 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Healthcare · Biotechnology · 39 employees
PLUR vs SNTI FAQ
Which is bigger, Pluri or Senti Biosciences?
Pluri (PLUR) is larger, with a market capitalization of $12.61M compared with $10.02M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, PLUR or SNTI?
PLUR returned -75.49% over the past 12 months, compared with -81.93% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are Pluri and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.